Tectonic Therapeutic Announces Participation at Investor Conferences in March

Rhea-AI Summary

Tectonic Therapeutic, Inc., a biotech company developing GPCR-targeted therapeutic proteins, announced CEO Alise Reicin's participation in two investor conferences in March 2022.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that Alise Reicin, MD, President and Chief Executive Officer, will be participating in two investor conferences in March:

• TD Cowen 44^th Annual Health Care Conference being held in Boston on March 4 – 6
• Leerink Partners Global Biopharma Conference being held in Miami on March 11 – 13

The Tectonic management team will host one-on-one meetings during both conferences. Interested investors should contact their TD Cowen and/or Leerink representative to schedule meetings.

About Tectonic Therapeutic

Tectonic Therapeutic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting GPCRs to develop novel therapies for patients inadequately served by current treatments. With its proprietary GEODe™ platform, Tectonic aims to unlock the therapeutic utility of some of the most difficult receptors in the class, where small molecule pharmacology may be intractable. In February 2024, Tectonic entered into a definitive agreement to merge with AVROBIO, Inc. (Nasdaq: AVRO). Tectonic is headquartered in Watertown, Massachusetts. Learn more at www.tectonictx.com and follow us @TectonicTx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240227911667/en/

Tectonic Therapeutic Contacts:

Investors:

Dan Ferry

LifeSci Advisors

daniel@lifesciadvisors.com

(617) 430-7576



Media:

Karen Sharma

MacDougall

ksharma@macdougall.bio

(781) 235-3060

Source: Tectonic Therapeutic, Inc.

FAQ

When and where will Alise Reicin, CEO of Tectonic Therapeutic, participate in investor conferences in March 2022?

Alise Reicin, CEO of Tectonic Therapeutic, will be participating in TD Cowen 44th Annual Health Care Conference in Boston on March 4-6 and Leerink Partners Global Biopharma Conference in Miami on March 11-13.

Who are the co-founders of Tectonic Therapeutic, Inc.?

Tectonic Therapeutic, Inc. was co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School.

What type of therapeutic proteins does Tectonic Therapeutic, Inc. develop?

Tectonic Therapeutic, Inc. develops GPCR (G-protein coupled receptor)-targeted therapeutic proteins.

How can interested investors schedule meetings with the Tectonic management team during the conferences?

Interested investors should contact their TD Cowen and/or Leerink representative to schedule one-on-one meetings with the Tectonic management team.